ORAL BCX 34 IN T CELL MALIGANCIES

T 细胞恶性肿瘤中口服 BCX 34

• 批准号: 6112812
• 负责人: MANSOOR N SALEH
• 金额: $ 2.95万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6112812
• 关键词: B lymphocyte; T lymphocyte; blood cell count; cell death; clinical research; clinical trial phase I; drug screening /evaluation; enzyme mechanism; human subject; human therapy evaluation; pharmacokinetics; purine nucleoside phosphorylase

BCX-34 is an experimental drug developed by BioCryst Pharmaceuticals Inc., and is being evaluated for use in the treatment of T-cell mediated disases. It has been tested extensively in animals to show that it is safe. Oral BCX-34 has been tested on 3 patients in an initial study to evaluate its safety. During the administration of a single oral dose and a 5 day oral course, no drug related adverse events were noted. This will be the first long term study investigating the effects of this drug in humans. The purpose of this trial is to determine the most effective and least toxic dose of medication needed for a therapeutic response. This will be measured by evaluating levels of drug in the blood and urine, monitoring blood counts for potential abnormalities and assessing the response of the skin and other organs to therapy.

BCX-34是BioCryst Pharmaceuticals Inc.开发的一种实验药物，正在评估其用于治疗T细胞介导的疾病的效果。它已在动物身上进行了广泛的测试，表明它是安全的。在一项初步研究中，口服 BCX-34 已在 3 名患者身上进行了测试，以评估其安全性。 在单次口服剂量和 5 天口服疗程期间，未发现与药物相关的不良事件。 这将是第一个调查该药物对人类影响的长期研究。该试验的目的是确定治疗反应所需的最有效且毒性最小的药物剂量。 这将通过评估血液和尿液中的药物水平、监测血细胞计数是否存在潜在异常以及评估皮肤和其他器官对治疗的反应来测量。